

## **U.S. Patent Awarded For Stroke And Traumatic Brain Injury**

*"Methods for treating neural cell swelling" provides Remedy Pharmaceuticals broad intellectual property protection.*

New York, NY, USA - October 23, 2007 – Remedy Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued patent 7,285,574 titled "Methods for treating neural cell swelling," which generally relates to the treatment of stroke and traumatic brain injury with  $NC_{Ca-ATP}$  channel inhibitors such as RP-1127.

Remedy is the exclusive worldwide licensee of the patent portfolio related to  $NC_{Ca-ATP}$  channels developed by Dr. J. Marc Simard, Professor of Neurosurgery, Pathology and Physiology at the University of Maryland School of Medicine. The Company also has its own portfolio of patent applications related to formulation and dosing of RP-1127.

"With this key patent in our intellectual property portfolio," said Sven Jacobson, Chief Executive Officer of Remedy, "we move one step closer to helping address the pressing need for a drug to treat acute central nervous system disorders, and by so doing, provide hope for hundreds of thousands of victims of stroke, traumatic brain injury and spinal cord injury."

### **About RP-1127**

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of  $NC_{Ca-ATP}$  channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

### **About Remedy Pharmaceuticals**

Remedy Pharmaceuticals, Inc. is a development stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: [info@remedypharmaceuticals.com](mailto:info@remedypharmaceuticals.com)